Additional Information
Book Details
Abstract
Get the most from your study time, and experience a realistic USMLE simulation with Rapid Review Pharmacology, 3rd Edition, by Drs. Thomas Pazdernik and Laszlo Kerecsen. This new edition in the highly rated Rapid Review Series is formatted as a bulleted outline with photographs, tables, and figures that address all the pharmacology information you need to know for the USMLE. And with Student Consult functionality, you can become familiar with the look and feel of the actual exam by taking a timed online test that includes more than 450 USMLE-style practice questions.
- Review all the information you need to know quickly and easily with a user-friendly, two-color outline format that includes High-Yield Margin Notes.
- Take a timed online test at www.studentconsult.com with more than 450 USMLE-style questions and full rationales for why every possible answer is right or wrong.
- Access the most current information with completely updated chapters, images, and questions.
- Profit from the guidance of series editor, Dr. Edward Goljan, a well-known author of medical study references, who is personally involved in content review.
- Easily review all essential information with new drug tables that detail mechanism of action, clinical uses, and adverse reactions.
- Study and take notes more easily with the new, larger page size.
- Practice with a new testing platform on USMLE Consult that gives you a realistic review experience and fully prepares you for the exam.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Common Laboratory Values | i | ||
| Rapid Review Series | ii | ||
| Title Page | iii | ||
| Copyright Page | iv | ||
| Dedication | v | ||
| Series Preface | vii | ||
| Special Features | vii | ||
| Acknowledgemnt of Reviewers | ix | ||
| Acknowledgements | xi | ||
| Contents | xiii | ||
| Section I: Principles of Pharmacology | 1 | ||
| Chapter 1: Pharmacokinetics | 1 | ||
| I. General (Fig. 1-1) | 1 | ||
| II. Drug Permeation | 1 | ||
| III. Absorption | 3 | ||
| IV. Bioavailability | 4 | ||
| V. Distribution | 5 | ||
| VI. Biotransformation: Metabolism | 7 | ||
| VII. Excretion | 9 | ||
| VIII. Kinetic Processes | 10 | ||
| Chapter 2: Pharmacodynamics | 14 | ||
| I. Definitions | 14 | ||
| II. Dose-Response Relationships | 14 | ||
| III. Drug Receptors | 15 | ||
| IV. Pharmacodynamically Altered Responses | 20 | ||
| V. Adverse Effects | 21 | ||
| VI. Federal Regulations | 22 | ||
| Section II: Drugs That Affect the Autonomic Nervous System and the Neuromuscular Junction | 23 | ||
| Chapter 3: Introduction to Autonomic and Neuromuscular Pharmacology | 23 | ||
| I. Divisions of the Efferent Autonomic Nervous System (ANS) (Fig. 3-1) | 23 | ||
| II. Neurochemistry of the Autonomic Nervous System | 24 | ||
| III. Physiologic Considerations | 27 | ||
| Chapter 4: Cholinergic Drugs | 29 | ||
| I. Cholinoreceptor Agonists | 29 | ||
| II. Cholinoreceptor Antagonists | 32 | ||
| III. Therapeutic summary of selected cholinergic drugs: (Table 4-2) | 34 | ||
| Chapter 5: Adrenergic Drugs | 36 | ||
| I. Adrenoreceptor Agonists | 36 | ||
| II. Adrenoreceptor Antagonists (Box 5-2) | 41 | ||
| III. Therapeutic summary of selected adrenergic drugs: (Table 5-2) | 44 | ||
| Chapter 6: Muscle Relaxants | 47 | ||
| I. Spasmolytics (Box 6-1) | 47 | ||
| II. Pharmacology of Motor End Plate | 48 | ||
| III. Therapeutic summary of selected muscle relaxants: (Table 6-2) | 50 | ||
| Section III: Drugs That Affect the Central Nervous System (CNS) | 52 | ||
| Chapter 7: CNS Introduction, and Sedative-Hypnotic and Anxiolytic Drugs | 52 | ||
| I. CNS Introduction | 52 | ||
| II. Basic Properties of CNS Depressant Drugs | 57 | ||
| III. Benzodiazepines (see Box 7-1) | 59 | ||
| IV. Barbiturates | 60 | ||
| V. Other Sedative-Hypnotics | 61 | ||
| VI. Alcohols | 61 | ||
| VII. Therapeutic summary of selected sedative-hypnotic drugs: (Table 7-1) | 62 | ||
| Chapter 8: Anesthetics | 64 | ||
| I. General Anesthetics | 64 | ||
| II. Local Anesthetics (Box 8-2) | 67 | ||
| Chapter 9: Anticonvulsant Drugs | 70 | ||
| I. Anticonvulsant Therapy | 70 | ||
| II. Drugs Used in the Treatment of Partial Seizures and Generalized Tonic-Clonic Seizures (Box 9-1; see also Table 9-2) | 70 | ||
| III. Absence (Petit Mal) Seizures and Drugs Used in their Treatment (see Box 9-1 and Table 9-2) | 74 | ||
| IV. Status Epilepticus and Drugs Used in Its Treatment (see Box 9-1 and Table 9-2) | 75 | ||
| V. Therapeutic Summary of Selected Anticonvulsant Drugs used in Treatment of Epilepsy (Table 9-3) | 75 | ||
| Chapter 10: Psychotherapeutic Drugs | 77 | ||
| I. Antipsychotic Drugs, Sometimes Referred to as Neuroleptic Drugs (Box 10-1) | 77 | ||
| II. Antidepressants and Mood Stabilizers (Box 10-2) | 81 | ||
| III. Drug used as mood stabilizers (Box 10-3) | 85 | ||
| IV. Attention-deficit/hyperactivity disorder (ADHD) Drugs (Box 10-4) | 87 | ||
| Chapter 11: Drugs Used in the Treatment of Parkinson's Disease | 89 | ||
| I. General Considerations | 89 | ||
| II. Drugs Used to Treat Parkinson’s disease (Box 11-1 and Fig. 11-2) | 89 | ||
| III. Therapeutic summary of selected drugs used to treat Parkinson’s disease: (Table 11-2) | 92 | ||
| Section IV: Drugs That Affect the Cardiovascular, Renal, and Hematologic Systems | 94 | ||
| Chapter 12: Antiarrhythmic Drugs | 94 | ||
| I. General Considerations | 94 | ||
| II. Arrhythmias and Their Treatment | 95 | ||
| III. Antiarrhythmic Drugs According to the Vaughn-Williams Classification (Box 12-1) | 96 | ||
| IV. Management of Atrial Fibrillation | 102 | ||
| V. Therapeutic summary of selected drugs used to treat arrhythmias: (Table 12-2) | 102 | ||
| Chapter 13: Antihypertensive Drugs | 104 | ||
| I. General Considerations | 104 | ||
| II. Diuretics (see Chapter 15) | 104 | ||
| III. Sympatholytic Drugs | 105 | ||
| IV. Vasodilators | 107 | ||
| V. Drugs That Affect the Renin Angiotensin System (RAS) | 109 | ||
| VI. Drugs Used in the Treatment of Hypertension Urgencies and Emergency (Box 13-2) | 110 | ||
| Chapter 14: Other Cardiovascular Drugs | 113 | ||
| I. General Considerations | 113 | ||
| II. Antianginal Drugs | 113 | ||
| III. Drugs That Affect Cholesterol and Lipid Metabolism | 115 | ||
| IV. Inotropic Agents and Treatment of Heart Failure (Box 14-3) | 119 | ||
| Chapter 15: Diuretics | 125 | ||
| I. General Considerations | 125 | ||
| II. Diuretics | 125 | ||
| III. Agents That Affect Water Excretion | 132 | ||
| Chapter 16: Drugs Used in the Treatment of Coagulation Disorders | 136 | ||
| I. General Considerations | 136 | ||
| II. Antithrombotic Drugs (Antiplatelet Drugs) | 136 | ||
| III. Anticoagulants (Box 16-2) | 139 | ||
| IV. Fibrinolytic (Thrombolytic) Drugs (Box 16-3) | 142 | ||
| V. Hemostatic Drugs and Blood Products (Box 16-4) | 145 | ||
| Chapter 17: Hematopoietic Drugs | 147 | ||
| I. General Considerations | 147 | ||
| II. Minerals | 147 | ||
| III. Vitamins | 149 | ||
| IV. Hematopoietic Growth Factors | 152 | ||
| V. Therapeutic summary of selected hematopoietic drugs (Table 17-5) | 152 | ||
| Section V: Analgesics | 154 | ||
| Chapter 18: Nonsteroidal Anti-Inflammatory Drugs And other Nonopioid Analgesic-Antipyretic Drugs | 154 | ||
| I. General Considerations | 154 | ||
| II. NSAIDs (Box 18-1) | 154 | ||
| III. Acetaminophen | 157 | ||
| IV. Therapeutic summary of selected nonsteroidal anti-inflammatory and related drugs (Table 18-2) | 158 | ||
| V. Drugs Used to Treat Migraine Headache (Box 18-2) | 158 | ||
| Chapter 19: Opioid Analgesics and Antagonists | 161 | ||
| I. Opioid Agonists (Box 19-1) | 161 | ||
| II. Mixed Opioid Agonists-Antagonists (Box 19-3) | 164 | ||
| III. Opioid Antagonists (Box 19-4) | 165 | ||
| IV. Therapeutic summary of selected opioid drugs (Table 19-3) | 165 | ||
| Section VI: Drugs That Affect the Respiratory and Gastrointestinal Systems and are Used to Treat Rheumatic Disorders and Gout | 167 | ||
| Chapter 20: Drugs Used in the Treatment of Asthma, Chronic Obstructive Pulmonary Disease and Allergies | 167 | ||
| I. General Considerations | 167 | ||
| II. Anti-inflammatory Agents Used to Treat Asthma (see Box 20-2; Fig. 20-1) | 167 | ||
| III. Bronchodilators (Box 20-3) | 172 | ||
| IV. Antihistamines Used in the Treatment of Allergies (Box 20-4) | 175 | ||
| Chapter 21: Drugs Used in the Treatment of Gastrointestinal Disorders | 178 | ||
| I. Peptic Disorders | 178 | ||
| II. Drugs That Decrease Gastric Acidity (Box 21-1) | 178 | ||
| III. Cytoprotective Agents (Box 21-2) | 180 | ||
| IV. Drugs Used in the Treatment of H. pylori Infection (see Chapter 27) | 181 | ||
| V. Therapeutic summary of selected drugs used to treat diseases of hyperacidity: (Table 21-1) | 181 | ||
| VI. Antidiarrheal Drugs (Box 21-3) | 181 | ||
| VII. Prokinetic Drugs (Box 21-4): | 183 | ||
| VIII. Antiemetic Drugs (see Box 21-4) | 184 | ||
| IX. Therapeutic summary of selected prokinetic and antiemetic drugs: (Table 21-3) | 186 | ||
| X. Drugs Used to Treat Irritable Bowel Syndrome (IBS) | 186 | ||
| XI. Drugs Used in the Treatment of Inflammatory Bowel Disease (IBD) | 187 | ||
| XII. Laxatives (Table 21-7) | 188 | ||
| Chapter 22: Immunosuppressive Drugs and Drugs Used in the Treatment of Rheumatic Disorders and Gout | 191 | ||
| I. Immunosuppressive Drugs (Box 22-1) | 191 | ||
| II Antiarthritic Drugs (Box 22-2): used to treat rheumatoid arthritis and act at various sites (Fig. 22-1). | 195 | ||
| III. Drugs Used in the Treatment of Gout (Box 22-3) | 199 | ||
| Section VII: Drugs That Affect the Endocrine and Reproductive Systems | 202 | ||
| Chapter 23: Drugs Used in the Treatment of Hypothalamic, Pituitary, Thyroid, and Adrenal Disorders | 202 | ||
| I. General Considerations | 202 | ||
| II. Hypothalamic Hormones and Related Drugs (Box 23-1) | 202 | ||
| III. Anterior Pituitary Hormones and Related Drugs (Box 23-2) | 205 | ||
| IV. Posterior Pituitary Hormones and Related Drugs | 210 | ||
| V. Thyroid Hormones and Related Drugs (Box 23-4) | 212 | ||
| VI. Adrenocorticosteroids (Box 23-5; Tables 23-6 and 23-7) | 216 | ||
| Chapter 24: Drugs Used in the Treatment of Diabetes Mellitus and Errors of Glucose Metabolism | 225 | ||
| I. General Considerations (Table 24-1) | 225 | ||
| II. Antidiabetic Agents (Box 24-1) | 228 | ||
| III. Hyperglycemic Agent | 234 | ||
| Chapter 25: Drugs Used in the Treatment of Bone and Calcium Disorders | 235 | ||
| I. General Considerations | 235 | ||
| II. Drugs That Affect Calcium Levels (Box 25-1) | 238 | ||
| Chapter 26: Drugs Used in Reproductive Endocrinology | 242 | ||
| I. Drugs That Act on the Uterus (Box 26-1) | 242 | ||
| II. Estrogens and Related Drugs (Box 26-2) | 245 | ||
| III. Contraceptives | 250 | ||
| IV. Androgens and Inhibitors (see Box 26-2; Fig. 26-3) | 252 | ||
| Section VIII: Anti-infective Drugs | 257 | ||
| Chapter 27: Antimicrobial Drugs | 257 | ||
| I. General Considerations | 257 | ||
| II. Cell Wall Synthesis Inhibitors (Box 27-1) | 261 | ||
| III. Drugs That Affect the Cell Membrane (Box 27-2) | 267 | ||
| IV. Protein Synthesis Inhibitors (Box 27-3) | 269 | ||
| V. Antimetabolites Used for Microorganisms (Box 27-4) | 275 | ||
| VI. Inhibitors of DNA gyrase: fluoroquinolones (Box 27-5) | 278 | ||
| Chapter 28: Other Anti-Infective Drugs | 281 | ||
| I. Antimycobacterial Drugs (Box 28-1) | 281 | ||
| II. Therapeutic Summary of Selected Drugs used in Treatment of Tuberculosis: Table 28-2 | 284 | ||
| III. Antiviral Drugs (Box 28-2) | 284 | ||
| IV. Antiparasitic Drugs (Box 28-3) | 290 | ||
| V. Antifungal Drugs (Box 28-4) | 296 | ||
| Section IX: Drugs Used in the Treatment of Cancer | 302 | ||
| Chapter 29: Chemotherapeutic Drugs | 302 | ||
| I. General Considerations | 302 | ||
| II. Drugs That Alter DNA ( Box 29-1) | 305 | ||
| III. Antimetabolites (Box 29-2) | 309 | ||
| IV. Mitotic Inhibitors (Box 29-3) | 312 | ||
| V. Podophyllotoxins (Box 29-4) | 313 | ||
| VI. Camptothecins (Box 29-5) | 313 | ||
| VII. Hormones and Hormone Regulators (Box 29-6) | 314 | ||
| VIII. Monoclonal Antibodies (Box 29-7) | 316 | ||
| IX. Signal Transduction Inhibitors (Box 29-8) | 317 | ||
| X. Miscellaneous Antineoplastic Agents (Box 29-9; see Table 29-4 for uses) | 317 | ||
| Section X: Toxicology | 319 | ||
| Chapter 30: Toxicology and Drugs of Abuse | 319 | ||
| I. General Principles of Toxicology | 319 | ||
| II. Symptoms and Treatment of Acute Poisoning (Table 30-1 and Table 30-2) | 320 | ||
| III. Teratogenic Effects of Specific Drugs: (Table 30-3) | 325 | ||
| IV. Dependence and Drugs of Abuse (Table 30-4). | 325 | ||
| Common Laboratory Values | 327 | ||
| Index | 331 |